RIDR-PI-103

RIDR-PI-103 is a reactive oxygen species (ROS) -induced agent release proagent with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103) . Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2].

Product Specifications

CAS Number

[2581114-71-6]

UNSPSC

12352005

Target

Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ridr-pi-103.html

Purity

98.02

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(CN)NC1=CC(N)=CC=C1OC2=CC=CC(C3=NC4=C(C(N5CCOCC5)=N3)OC6=NC=CC=C64)=C2

Molecular Formula

C27H25N7O4

Molecular Weight

511.53

References & Citations

[1]Mishra R, et al. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS) -Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci. 2021;22 (4) :2088. Published 2021 Feb 19. |[2]Rosalin Mishra, et al. Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA) : AACR; Cancer Res 2020;80 (4 Suppl) :Abstract nr P3-10-04.